Target intelligence / Profile preview

Lamin B2 (LMNB2)

Target
LMNB2
Molecular classification
Intermediate filament protein (type V intermediate filament), Component of the nuclear lamina
01

Overview

Lamin B2 is a type V intermediate filament protein encoded by the LMNB2 gene. It is a major component of the nuclear lamina—a filamentous meshwork adjacent to the inner nuclear membrane—which confers structural stability to the nucleus and participates in chromatin organization and gene expression. Lamin B2 is essential for maintaining nuclear mechanics during development, especially neuronal migration and brain organogenesis. LMNB2 promotes cell cycle progression and proliferation, and its overexpression is implicated in several cancers, including triple-negative breast cancer and colorectal cancer. LMNB2 is also linked to rare genetic conditions such as progressive myoclonic epilepsy and microcephaly. While currently not directly targeted by approved drugs, LMNB2 represents an emerging therapeutic and biomarker target in oncology and neurodevelopmental research

Other names
Lamin B2LMNB2EPM9MCPH27epididymis secretory sperm binding proteinlamin B3LMN2
02

Mechanism of action

No mechanism established for clinical drugs targeting LMNB2 directly; experimental silencing approaches (e.g., shRNA, siRNA) decrease LMNB2 expression and suppress tumor proliferation/apoptosis in cancer models

03

Biological functions

Nuclear stabilityChromatin structure maintenanceGene expression regulationCell cycle progression (mitosis, nuclear envelope breakdown and reassembly)Neuronal migration and cortical layeringCell proliferation (especially in cancer)
04

Disease associations

Cancer (triple-negative breast cancer; colorectal cancer)Neurodevelopmental defects (e.g., lissencephaly-like brain malformations)Epilepsy, progressive myoclonic, 9Microcephaly 27, primary, autosomal dominantAcquired partial lipodystrophy
05

Safety considerations

Neurodevelopmental risk (deficiency during development leads to malformations and neuronal migration defects)Potential risk of impairing cell cycle and proliferation in non-target tissues if targeted therapeutically
06

Biomarkers

High LMNB2 expression as a prognostic biomarker in breast cancer and colorectal cancer (correlates with poor prognosis, larger tumors, metastatic burden)

Beyond the preview

Go deeper on Lamin B2 (LMNB2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lamin B2 (LMNB2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call